MedTrace Logo

Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant

NCT00788827 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This is a phase I study to assess the safety and tolerability of infusing expanded stem cells into the pancreas of patients with type I diabetes and a successful renal transplant. The stem cells used in this study occur naturally in the body and are collected from each recipient by a procedure called leukapheresis. The cells are then expanded and differentiated into insulin-like cells in a sterile suite before being injected into the body or tail of the pancreas of the recipient.

Conditions

Interventions

BIOLOGICAL

Autologous CD34+ stem cells

Up to 5 x 10 log 8 of autologous stem cells on a single occasion

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Charles Pusey, MD · Imperial College London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788827 on ClinicalTrials.gov